Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients

Gene Therapy

Volumn 7, Issue 8, 2000, Pages 637-643

  Stallwood, Y ^a   Fisher, K D ^a   Gallimore, P H ^a   Mautner, V ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adenovirus; Antibodies; Ascitic fluid; Isotype; Neutralisation

Indexed keywords

GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADENOVIRUS; ADVANCED CANCER; ARTICLE; ASCITES FLUID; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALIA;

EID: 0034059394     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301152     Document Type: Article

References (25)

1. Searle P, Mautner V. Adenoviral vectors: not to be sneezed at. Gene Therapy 1998; 5: 725-727.
2. Zhang W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Therapy 1999; 6: 113-138.
3. Runyon BA. Editorial: malignancy-related ascites and ascitic fluid 'Humoral tests of malignancy'. J Clin Gastroenterol 1994; 18: 94-98.
4. Puls LE et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996; 61: 109-112.
5. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 1993; 53: 2631-2643.
6. Horwitz MS. Adenoviruses In: Fields BN et al (eds). Virology. Lippincott-Raven: Philadelphia, 1996, pp 2149-2169.
7. Shenk T. Adenoviridae: The viruses and their replication In: Fields BN et al (eds). Virology. Lippincott-Raven: Philadelphia, 1996, pp 2111-2148.
8. Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 1996; 70: 1836-18445.
9. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992; 73: 1429-1433.
10. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens created barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
11. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
12. Van Ginkel FW et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol 1997; 159: 685-693.
13. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
14. Wilson JM. Vehicles for gene therapy. Nature 1993; 365: 691-692.
15. Molnar-Kimber KL et al. Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133.
16. Chirmule N et al. Immune responses to adenovirus and adenoassociated virus in humans. Gene Therapy 1999; 6: 1574-1583.
17. Bastian A, Bewig B. Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid. Gene Therapy 1999; 6: 637-642.
18. Harvey BG et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73: 6729-6742.
19. Gahery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72: 2388-2397.
20. Wohlfart C. Neutralisation of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988; 62: 2321-2328.
21. Mastrangeli A et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
22. Roy S, Shirley PS, McClelland A, Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998; 72: 6875-6879.
23. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
24. Mautner V. Methods for growth and purification of enteric adenovirus type 40. In: Wold WSM (ed). Adenovirus Methods and Protocols. Humana Press: New Jersey, 1999, pp 283-294.
25. Lemay P, Boudin M, Milleville M, Boulanger P. Human adenovirus type 2 protein IIIa.I. Purification and characterisation. Virology 1980; 101: 131-143.